摘要
弥漫大B细胞淋巴瘤(diffuselarge B celllymphoma,DLBCL)是成人淋巴瘤中最常见的一种类型,在临床表现、组织形态和预后等多方面具有异质性。DLBCL的发病率在欧美国家约占非霍奇金淋巴瘤(NHL)的31%,
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2013年第5期458-460,共3页
Chinese Journal of Hematology
参考文献23
-
1李小秋,李甘地,高子芬,周小鸽,朱雄增.中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J].诊断学理论与实践,2012,11(2):111-115. 被引量:242
-
2Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse largeZ B-cell lymphoma. N Engl J Med, 2002, 346: 1937-1947.
-
3Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103 : 275-282.
-
4Schaefer NG, Hany TF, Taverna C, et al. Non-hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging do We need contrast-enhanced CT?. Radiology, 2004, 232:823-829.
-
5Hutching M, Loft A, Hansen M, et al. Positron emission tomo- graphy with or without computed tomography in the primary staging of Hodgkin' s lymphoma. Haematologica, 2006, 91:482-489.
-
6Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomo- graphy for early response assessment in diffuse large B cell lympho- ma: where we now? Leuk Lymphoma, 2009, 50:1931-1936.
-
7Mikhaeel NG, Timothy AR, O' Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non- Hodgkin' s Lymphoma-comparison with CT. Leuk Lymphoma, 2000, 39:543-553.
-
8Haioun C, Itti E, Rahmouni A, et al. [ 18F] fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 2005, 106:1376-1381.
-
9Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpreta- tion. J Nucl Med, 2011, 52:386-392.
-
10Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for predic- tion of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med, 2007,48:1626-1632.
共引文献241
-
1王瑾,郭睿,李彪,张晓哲.^(18)F-FDG PET/CT显像动态评估自然杀伤/T细胞淋巴瘤(鼻型)治疗预后[J].诊断学理论与实践,2022,21(6):702-709.
-
2闫淑芳,李思静,刘波,杨美虹,李新霞.头颈部结外弥漫大B细胞淋巴瘤的临床病理特征及预后分析[J].新疆医学,2021,51(7):743-748. 被引量:1
-
3陈剑秋,朱春生,耿明,林家峰,叶犇,安丰伟,王宝东,李跟红.原发性鼻腔淋巴瘤临床病理及CT征象分析[J].中华消化病与影像杂志(电子版),2013(6):289-293. 被引量:1
-
4王华庆,章馨允,曾珠.PET/CT评估弥漫大B细胞淋巴瘤治疗效果的价值[J].循证医学,2012,12(5):265-268.
-
5崔杰,张连生,席亚明,孙延庆,周俊,王金穗,董驰,杨荣,刘玉琴,曾鹏云.兰州地区多中心协作淋巴瘤病理类型分布特点[J].甘肃医药,2012,31(12):884-887. 被引量:3
-
6沈扬,尹婉宜,贾晓辉,张丽红,孙士斌,刘擘.肠病相关性T细胞淋巴瘤1例并文献复习[J].疑难病杂志,2013,12(6):473-474. 被引量:1
-
7张欣,王洁,艾丽梅.783例淋巴瘤患者流行病学分析[J].现代预防医学,2013,40(20):3908-3912. 被引量:21
-
8邹译娴,姜浩.肿瘤相关性miRNA与非霍奇金淋巴瘤关联研究进展[J].中南医学科学杂志,2013,41(5):520-525. 被引量:2
-
9席昱,胡晓抒,吴剑秋.利妥昔单抗联合化疗治疗弥漫性大B细胞淋巴瘤的临床观察[J].药学与临床研究,2013,21(5):566-569. 被引量:5
-
10张弦,罗志飞,蒙秋萍,解娜,黄幼生,王明华,翁阳.海南地区淋巴组织增生性病变病理分型与EBV感染的相关性分析[J].海南医学,2013,24(22):3292-3295. 被引量:2
同被引文献23
-
1王晶,克晓燕,赵灵芝,李敏,景红梅,王继军,赵伟,高子芬.74例弥漫大B细胞淋巴瘤的预后相关因素分析[J].中华血液学杂志,2007,28(10):667-670. 被引量:17
-
2Merie E, Gunduz A, Turedi S, et al. The prognostic value of neuron- specific enolase in head trauma patients[J]. J Emerg Med, 2010, 38: 297-301.
-
3Osterlundh G, Bjure J, Lannering B, et al. Regional cerebral blood flow and neuron-specific enolase in cerebrospinal fluid in children with acute lymphoblastic leukemia during induction treatment [J]. J Pediatr Hematol Oncol, 1999, 21: 378-383.
-
4Delsol G. The 2008 WHO lymphoma classification [J]. Ann Pathol, 2008, 28: 20-24.
-
5Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome[J]. Blood, 2005, 106: 1376-1381.
-
6Massarelli G, Onida GA, Piras MA, et al. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas[J]. Anticancer Res, 1999, 19: 3933- 3938.
-
7Wang L, Liu P, Chen X, et al. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center Bcell-like subtype of diffuse large B-cell lymphoma treated with rituximab-basedimmunochemotherapy [J]. MedOncol, 2012, 29: 2153-2158.
-
8Zhang W, Potrovita I, Tarahin V, et al. Neuronal activation of NF- kappaB con-tributes to cell death in cerebral ischemia [J]. J Cereb Blood Flow Metab, 2005, 25: 30-40.
-
9Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells[J]. J Exp Med, 2001, 194:1861-1874.
-
10Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal trans-ducer and activator of transcription 3 and nuclear factor- {kappa}B pathways in subty- pes of diffuse large B-cell lymphoma [J]. Blood, 2008, 111: 3701-3713.
引证文献3
-
1陈连香,肖镇,黄彬涛,王威.神经元特异性烯醇化酶在弥漫大B细胞淋巴瘤缓解患者血清中的表达及其意义[J].白血病.淋巴瘤,2014,23(2):103-106. 被引量:3
-
2杨艳迪,陆滢,叶佩佩.PEG-rhG-CSF预防弥漫大B细胞淋巴瘤患者化疗后中性粒细胞缺乏的效果观察[J].浙江医学,2020,42(6):587-590. 被引量:4
-
3胡通林,商臻,徐金环,肖毅.自体造血干细胞移植序贯靶向CD19和CD22嵌合抗原受体T细胞治疗肾弥漫大B细胞淋巴瘤中枢神经系统复发1例并文献复习[J].白血病.淋巴瘤,2022,31(3):165-169.
二级引证文献7
-
1刘瑞廷,王国荣,邱健,王小强,阎立昆,李小军,刘昌.DNA结合蛋白A在结直肠癌组织和细胞中的表达及其临床意义[J].肿瘤研究与临床,2015,27(8):505-509. 被引量:3
-
2夏菲,李锦成.右美托咪定用于脑血管瘤术中脑保护的疗效观察[J].中国药房,2015,26(29):4135-4137. 被引量:1
-
3王蕾,颜晓菁,何娟.PEG-rhG-CSF与G-CSF预防及治疗化疗后中性粒细胞缺乏的效果比较[J].现代肿瘤医学,2021,29(7):1215-1219. 被引量:8
-
4李小丹,郭红燕,李圆.初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子在卵巢癌初始肿瘤细胞减灭术后化疗的价值[J].中国微创外科杂志,2022,22(3):197-201. 被引量:8
-
5赖燕辉,黄小琴,梁清海.二级预防药物对恶性肿瘤化疗患者中性粒细胞减少症发生率的影响[J].当代医药论丛,2022,20(14):41-44.
-
6丁笑笑,梁珍伟,王雯雯,陈建霖,郭艳荣.隔物灸辅助昂丹司琼预防淋巴瘤化疗相关恶心、呕吐的效果[J].中国医药导报,2024,21(8):149-152.
-
7瞿杭炯,方凯.脊髓炎合并大B细胞恶性淋巴瘤1例[J].临床合理用药杂志,2016,9(4):6-6.
-
1林之光,许小平.弥漫性大B细胞淋巴瘤预后因素的研究进展[J].中国肿瘤生物治疗杂志,2008,15(6):594-597.
-
2韩泽,严智昌.CD10、Bcl-6、MUM1的表达与弥漫大B细胞淋巴瘤预后的关系[J].肿瘤预防与治疗,2010,23(1):71-73. 被引量:1
-
3徐燕敏,许继红,徐婷,李望莉,张霞.Ang-2与Survivin蛋白在B细胞非霍奇金淋巴瘤的表达及临床意义[J].现代肿瘤医学,2012,20(12):2622-2626. 被引量:1
-
4孙春艳,刘新月,陈燕,刘芳.Anticancer Effect of Curcumin on Human B Cell non-Hodgkin's Lymphoma[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2005,25(4):404-407.
-
5江新苗,李文瑜.2016年淋巴瘤研究新进展[J].循证医学,2017,17(1):17-19. 被引量:2
-
6韩晓东,刘擘,田延锋,李芳,赵增仁,翟从劼.miR-218在乳腺癌组织中的表达及其对乳腺癌MCF-7细胞生物学行为的影响[J].肿瘤,2015,35(7):794-800. 被引量:4
-
7刘宇宏,刘延香,黄高昇,王娟红,王文清,张伟平,李袁飞,王璐,王迪,王哲.B细胞非霍奇金淋巴瘤PBK/TOPK表达与增殖活性的关系[J].临床与实验病理学杂志,2006,22(5):541-544. 被引量:3
-
8宋恩霖,熊小亮,艾有生,刘繁荣,朱静,刘勇.Ki-67在GCB及non-GCB弥漫性大B细胞淋巴瘤中的表达及意义[J].江西医药,2011,46(2):111-114. 被引量:7
-
9全晓广,张晓薇.细胞凋亡在子宫肌瘤组织射频治疗中的作用[J].现代临床医学生物工程学杂志,2006,12(4):346-349. 被引量:2
-
10叶云飞,肖何,罗佳,皮国成,王阁.原发性肝癌B细胞异位基因2的表达及临床意义[J].第三军医大学学报,2017,39(7):685-690. 被引量:7